Valuation: Amicus Therapeutics, Inc.

Market Cap 4.55B 4B 3.77B 3.44B 6.44B 437B 6.49B 45.27B 17.54B 222B 17.08B 16.71B 723B P/E 2024
-51.1x
P/E 2025 -162x
Enterprise Value 4.7B 4.13B 3.9B 3.55B 6.65B 451B 6.7B 46.75B 18.12B 230B 17.64B 17.26B 747B EV / Sales 2024
5.69x
EV / Sales 2025 7.18x
Free-Float
99.31%
Yield 2024 *
-
Yield 2025 -
1 day+0.21%
6 months+0.49%
Current year+1.76%
Current year 14.2
Extreme 14.205
14.5
1 year 7.68
Extreme 7.68
14.5
3 years 5.51
Extreme 5.51
14.57
5 years 5.51
Extreme 5.51
14.57
10 years 4.41
Extreme 4.41
25.39
Date Insider Type Main position Quantity % Market Cap. Importance
27/4/26 Issuer sale

General Counsel

1,264,993 0.4029%
27/4/26 Issuer sale

Director

395,940 0.1261%
27/4/26 Issuer sale

Chairman

419,487 0.1336%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-.--%+77.57%+18.19% 4.55B
+1.46%+5.87%+5.75%+33.71% 47.56B
+2.67%+2.31%+47.50%+38.37% 44.09B
-1.38%+3.42%+9.39%+88.88% 41.5B
+4.78%+2.01%+352.12%+566.20% 40.88B
-0.62%+0.11%+1.12%+46.02% 29.67B
+0.56%+0.67%+25.08%+155.71% 17.23B
+2.05%+4.04%+24.47%+41.67% 15.06B
+3.39%-6.86% - - 14.65B
+7.38%+17.54%-2.25% - 13.82B
Average +2.01%+0.64%+60.09%+123.59% 26.9B
Weighted average by Cap. +1.84%+0.95%+71.98%+145.05%

Financials

2024 2025
Net sales 528M 465M 438M 400M 747M 50.71B 753M 5.26B 2.04B 25.81B 1.98B 1.94B 83.99B 634M 558M 526M 480M 897M 60.88B 904M 6.31B 2.45B 30.98B 2.38B 2.33B 101B
Net income -56.11M -49.35M -46.52M -42.45M -79.38M -5.39B -80M -558M -216M -2.74B -211M -206M -8.92B -27.11M -23.85M -22.48M -20.51M -38.35M -2.6B -38.65M -270M -105M -1.32B -102M -99.58M -4.31B
Net Debt 194M 170M 161M 147M 274M 18.59B 276M 1.93B 747M 9.46B 727M 711M 30.79B 149M 131M 123M 113M 211M 14.29B 212M 1.48B 574M 7.27B 559M 547M 23.66B
Logo Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Employees
511
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. FOLD Stock